| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1688 | |
| Phytochemical name or plant extracts | Saikosaponin b2 (SSb2) | |
| PMID | 31257464 | |
| Literature evidence | In conclusion, these results indicated that SSb2 may be a potential antitumor drug for the treatment of breast cancer, which acts by suppressing proliferation and migration by downregulating the STAT3 signalling pathway and inhibiting the expression of VASP, MMP2 and MMP9 expression. | |
| IUPAC name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponin | |
| Source of phytochemicals or plant Extracts | Radix Bupleuri | |
| Geographical availability | NA | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | STAT-3, VASP, MMP2, MMP9, c-myc, Cyclin D1 | |
| Gene or Protein evidence | It was further identified by western blot analysis that SSb2 treatment reduced levels of phosphorylated STAT3, VASP, matrix metallopeptidase (MMP) 2 and MMP9 in MCF‑7 compared with the untreated cells. | |
| Target pathways | SSb2 significantly reduced protein expression of c-myc and cyclin D1, which are associated with cell proliferation via the STAT3 signalling pathway | |
| IC50 | NA | |
| Potency | In conclusion, these results indicated that SSb2 may be a potential antitumor drug for the treatment of breast cancer, which acts by suppressing proliferation and migration by downregulating the STAT3 signalling pathway and inhibiting the expression of VASP, MMP2 and MMP9 expression. | |
| Cell line/ mice model | MCF-7 | |
| Additional information | SSb2 inhibited proliferation and migration of MCF-7 cells by reducing the activation of STAT3, and inhibiting VASP, MMP2 and MMP9 protein expression. | |
| PubChem ID | 21637642 | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |